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Abstract
Background
Management guidelines for chronic obstructive pulmonary disease (COPD) recommend
that inhaled corticosteroids (ICS) are prescribed to patients with the most severe symp-
toms. However, these guidelines have not been widely implemented by physicians, leading
to widespread use of ICS in patients with mild-to-moderate COPD. Of particular concern is
the potential risk of worsening diabetic control associated with ICS use.
Here we investigate whether ICS therapy in patients with COPD and comorbid type 2
diabetes mellitus (T2DM) has a negative impact on diabetic control, and whether these
negative effects are dose-dependent.
Methods and Findings
This was a historical matched cohort study utilising primary care medical record data from
two large UK databases. We selected patients aged40 years with COPD and T2DM, pre-
scribed ICS (n = 1360) or non-ICS therapy (n = 2642) between 2008 and 2012. The primary
endpoint was change in HbA1c between the baseline and outcome periods. After 1:1 match-
ing, each cohort consisted of 682 patients. Over the 12–18-month outcome period, patients
prescribed ICS had significantly greater increases in HbA1c values compared with those
prescribed non-ICS therapies; adjusted difference 0.16% (95% confidence interval [CI]:
0.05–0.27%) in all COPD patients, and 0.25% (95% CI: 0.10–0.40%) in mild-to-moderate
COPD patients. Patients in the ICS cohort also had significantly more diabetes-related gen-
eral practice visits per year and received more frequent glucose strip prescriptions, com-
pared with those prescribed non-ICS therapies. Patients prescribed higher cumulative
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doses of ICS (>250 mg) had greater odds of increased HbA1c and/or receiving additional
antidiabetic medication, and increased odds of being above the Quality and Outcomes
Framework (QOF) target for HbA1c levels, compared with those prescribed lower cumula-
tive doses (125 mg).
Conclusion
For patients with COPD and comorbid T2DM, ICS therapy may have a negative impact on
diabetes control. Patients prescribed higher cumulative doses of ICS may be at greater risk
of diabetes progression.
Trial Registration
ENCePP ENCEPP/SDPP/6804
Introduction
Chronic obstructive pulmonary disease (COPD) is a common and underdiagnosedmedical
condition that is projected to become the third leading cause of death worldwide by 2020.[1, 2]
Current UK and international guidelines on COPDmanagement recommend initial treatment
with long-actingmuscarinic antagonists (LAMA) or long-acting β2-agonists (LABA), with
high-dose inhaled corticosteroids (ICS) reserved for patients with more severe disease. Bron-
chodilators can be prescribed as monotherapy, in combination with each other, or with an
additional drug (eg LABA/LAMA or ICS/LABA).[3, 4] There is evidence to suggest that ICS/
LABA therapy reduces exacerbations and increases quality of life in appropriate patients.[5]
However, an increasing body of evidence suggests a link between the prescription of high doses
of ICS and the risk of comorbidities, such as cataracts, osteoporosis and pneumonia[6–10]—
events clearly associated with systemic/oral corticosteroids. Therapy with ICS has specifically
been associated with an increased serum glucose concentration, which may be particularly
important for patients with COPD in whom co-morbid type 2 diabetes mellitus (T2DM) is
more prevalent than in the general population.[11–13] The potential risk of reduced glycaemic
control is of further concern for these patients due to their high obesity rates, and because the
licensed doses of ICS are high compared with those prescribed to patients with asthma.[14, 15]
International guidelines recommend that ICS treatment should be reserved for patients
with COPD who have severe airflow limitation and/or a high risk of exacerbations, ie groups C
and D of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) staging.[3, 4]
This is in agreement with current UK license specifications.[5]Contrary to guidelines, how-
ever, ICS are frequently prescribed for patients in GOLD groups A and B who have mild or
moderate spirometrical COPD, fewer symptoms, and a lower risk of exacerbations than those
in groups C and D.[16–18] This means that more patients could be exposed to the potential
risks of ICS treatment than necessary. The reasons for these prescribing patterns are likely to
be complex and may include diagnostic uncertainty, therapeutic confusion with other respira-
tory diseasemanagement guidelines, or co-existing asthma and COPD.[16–18]
A large study by Suissa et al.[6] based on prescription claims for a broad group of respira-
tory patients, most of them with a likely COPD diagnosis, suggested that ICS use might be
associated with increased diabetes rates. However, there is a lack of real-life biochemical data
on the potential adverse effects of ICS treatment on comorbidities in patients with confirmed
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COPD diagnoses. Further information is needed on the specific effects of ICS therapy on gly-
caemic control and progression to insulin in patients with COPD and comorbid T2DM. The
aim of this historical matched cohort study was to investigate whether ICS therapy in a UK
patient population with COPD and comorbid T2DM has a negative impact on diabetes con-
trol. Specifically, we assessed whether ICS use is associated with an increase in glycated haemo-
globin (HbA1c) levels in these patients. In addition, we assessed whether ICS use influences
other indicators of diabetes control and the risk of diabetes progression, especially in patients
who should not be prescribed ICS according to COPDmanagement guidelines, and whether
these potential effects of ICS use are dose-dependent.
Methods
Study design
This historical, matched cohort study consisted of a baseline period for patient characterisation,
during 2008–2012, followed by an outcome period during which the study endpoints were evalu-
ated. The baseline and outcome periodswere separated by the index date, defined as either a first
prescription of an ICS (ICS cohort), or a first/additional prescription of non-ICS inhaled respira-
tory therapy (non-ICS cohort). To capture all valid HbA1c measurements before and after the
index date, the baseline and outcome periods covered between 12 and 18 months each.
The study protocol (included in supporting information, as S1 Protocol) was designed prior
to data extraction by an independent steering committee and registered with the European
Network of Centres for Pharmacoepidemiologyand Pharmacovigilance (ENCePP registration
number ENCEPP/SDPP/6804).
Data Source
To maximise the number of patients available, data were extracted from two large UK primary
care databases and combined into a single dataset. The Clinical Practice Research Datalink
(CPRD) contains de-identified longitudinal data frommore than 680 subscribing practices, is
well validated and frequently used for medical and health research.[19] The Optimum Patient
Care Research Database (OPCRD) is a quality-controlled and respiratory-focused research
database containing anonymous, longitudinal data for over two million patients from over 500
UK practices. The database has received a favourable opinion from the Health Research
Authority of the UK NHS for clinical research use (REC reference: 15/EM/0150).[20]
Patients
Eligible patients (40 years old at the index date) had a spirometry-test validated Quality and
Outcomes Framework (QOF) coded diagnosis of COPD at any time (ratio of forced expiratory
volume in 1 second to forced vital capacity [FEV1/FVC]<0.7), and a QOF-coded diagnosis of
T2DM before the index date. The code lists we used for COPD and T2DM can be found in
Supplementary methods (S1 File). The QOF is the UK National Health Servicepay-for-perfor-
mance scheme that provides an incentive for practices to deliver better patient care and
includes the creation of high-quality electronic disease registers[21, 22], and is known to have
improved diabetes care.[23] Patients had to have at least 1 full year of data available during the
baseline period, including HbA1c data available at least once within the baseline period, as well
as at least once between 20 days and 18 months in the outcome period. The 20-day limit was
chosen on the basis that HbA1c levels have been reported to plateau 20 days after intensification
of glucose lowering therapy and remain comparable for a further 100 days,[24, 25] while the 18
month limit was designed to capture all valid HbA1c readings, assuming HbA1c values were
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recorded at least every 15 months as per QOF diabetes indicators specified for the study
period.[22] For the ICS cohort, patients were included if they had a first prescription for ICS
between 2008 and 2012, with a medication possession ratio for ICS of50% in the outcome
period.[22] For the non-ICS cohort, patients were included if they had a first or additional pre-
scription for non-ICS therapy between 2008 and 2012, and no ICS therapy prior to an HbA1c
reading in the outcome period. Exclusion criteria included any record of type 1 diabetes and
any prescriptions for maintenance oral corticosteroids in the year before the index date.
Study endpoints
Primary and secondary outcomes of the study are outlined in Table 1. The primary outcome
measure was a change in HbA1c value, observedover a period of 12–18 months. The change
was defined as the difference between baseline and outcome HbA1c values. The baseline HbA1c
referred to the most recent value prior to the index date, and the outcome HbA1c referred to
the last value in the outcome period. Secondary outcomes focused on other measures of diabe-
tes control, defined as increase in HbA1c and/or addition of antidiabetic drugs, number of
patients off the HbA1c QOF target, diabetes-related GP visits, hospitalisations, glucose strip
prescriptions, and progression to insulin (Table 1). The time to progression to insulin, and the
effects of the cumulative dose of ICS on diabetes control, were also investigated.
Table 1. Study endpoints and matching criteria.
Study endpoints
• Primary endpoint
 Change in HbA1c from baseline to outcome period
• Secondary endpoints
 Increase in HbA1c* and/or the addition of antidiabetic medication from baseline to outcome period
 Number of patients off the QOF target for HbA1c (HbA1c >7.5%)
 Change in diabetes-related GP visits, hospitalisations, and glucose strip prescriptions†
 Progression of ongoing diabetes treatment to insulin by time or dose
Matching criteria Categories
Sex Male / female
Age (±5 years at index date‡) NA
Smoking status at index date Non-smoker / current smoker / ex-smoker
BMI at index date Underweight / normal weight / overweight / obese
mMRC score[4] at index date Missing / 0–1 /2
Exacerbations§ during baseline 0–1 /2
FEV1, % predicted at index date Missing / <50% /50%
HbA1c¶ ±1 DCCT (%) during baseline NA
Antidiabetic medication during baseline None / non-insulin / insulin
*Increase in HbA1c was defined as a change of0.5% from baseline to outcome period. Antidiabetic
medication during baseline was categorised as 1, 2 or3 of non-insulin or insulin, and any progression from
baseline to outcome within these categories was recorded as addition of an antidiabetic drug.
†GP visits: change in annual rate from baseline to outcome period; hospitalisations: increase from baseline
to outcome period; glucose strip prescriptions: increase (>0.5 per year) from baseline to outcome period.
‡The index date was defined as the date of first ICS prescription or first/additional non-ICS prescription.
§Defined as the number of acute oral corticosteroid courses and antibiotic prescriptions for a lower
respiratory tract infection.
¶Most recent value within 18 months prior to the index date.
BMI = body mass index; DCCT = Diabetes Control and Complications Trial units; FEV1 = forced expiratory
volume in 1 second; GP = general practice; HbA1c = glycated haemoglobin; mMRC = modified Medical
Research Council; NA = not applicable; QOF = Quality and Outcomes Framework.
doi:10.1371/journal.pone.0162903.t001
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Statistical analysis
The study was powered on the primary outcome, change in HbA1c value. Based on a previ-
ous study[26] and unpublished data, detecting a mean HbA1c change of 0.25% with 90%
power to reject the null hypothesis, (no difference in change and using a two-sided t-test
with a 5% significance level), assuming that the common standard deviation is 1.1, required
408 patients in each cohort. Records from the OPCRD and CPRD databases were combined
into a single dataset. Patient selection was then carried out according to inclusion/exclusion
criteria, resulting in 1360 and 2642 patients in the ICS and non-ICS cohorts, respectively
(S1 Fig, S1 File).
A baseline analysis of unmatched patients revealed significant differences between the ICS
and non-ICS cohorts (Table 2). As might be expected, patients in the ICS cohort generally had
more severe COPD than those in the non-ICS cohort with higher proportions having a modi-
fied British Medical Research Council (mMRC) score2,[4] or a %predicted FEV1<50.
Higher percentages of patients in the ICS cohort had also received1 acute course of oral cor-
ticosteroids or had experienced exacerbations during the baseline period. Conversely, a higher
proportion of patients in the non-ICS cohort were prescribed insulin before the index date.
Characteristics were describedusing summary statistics and compared using t-tests, Mann-
Whitney U tests, or Pearson’s χ2 tests. Patients were then matched in a 1:1 ratio based on pre-
specifieddemographic characteristics, COPD severity and therapies, diabetes control, and
potentially confounding comorbidities (Table 1, S2 Fig). A missing category was created for
key variables to ensure no data was lost during matching.
The primary outcome (change in HbA1c value) was compared using a generalised linear
model, and results were reported as adjusted within- and between-group (ICS vs non-ICS) dif-
ferences in change from baseline to outcome with 95% confidence interval. Binary outcomes
were analysed using conditional logistic regression models and results were reported as odds
ratios with 95% confidence intervals. Potential confounders (listed in S1 File), were checked for
collinearity using Spearman’s correlation coefficients.Dose-dependent outcomes were investi-
gated according to cumulative ICS dose exposuremeasured in fluticasone propionate equiva-
lents (fluticasone propionate:extrafine beclomethasone dipropionate [BDP]:budenoside:non-
extrafine BDP in a 1:1:2:2 ratio).[27–29] Time to progression to insulin in the outcome period
was assessed using a Cox proportional hazards regression model. The proportional hazards
assumption was checked before models were fitted. Analyses were carried out on the full data
set of matched patients, as well as on a subgroup of patients with mild-to-moderate COPD,
who were identified as belonging to GOLD groups A or B (more information on these groups
can be found in S1 File). As this subgroup represents patients in which ICS prescribing may
not be appropriate, the number needed to harm (NNH, 95% CI) was estimated, as the inverse
of the risk difference. Finally, endpoints were compared in ICS cumulative dose subgroups
(>125-250mg and>250mg, versus125mg), to investigate a dose-dependent relationship.
This analysis was carried out in the full study sample.
All potential confounding variables (listed in S1 File) were investigated in the final multivar-
iate models, but were only included if they were significant in the model, or if their exclusion
materially changed the main effect of interest. If a potential adjusting variable had strong co-
linearity with another adjusting variable, the most significant was retained in the model. Analy-
ses were performed using R statistical software (R Foundation for Statistical Computing, Aus-
tria), SPSS Statistics 22 (IBM SPSS Statistics, UK) and SAS 9.3 (SAS Institute, UK). Results
were reported in accordance with STROBE guidelines for reporting cohort studies (S1
Checklist).
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Table 2. Key baseline demographic and clinical characteristics for unmatched and matched datasets comparing patients with COPD and type 2
diabetes on either ICS or non-ICS therapy. Additional baseline data can be found in S1 Table (S1 File).
Key patient characteristics Unmatched Matched
ICS (n = 1360) non-ICS (n = 2642)* ICS (n = 682) non-ICS (n = 682)*
Age (years) Mean (SD) 70.5 (9.3) 70.8 (9.1) 70.4 (7.8) 70.5 (7.7)
Age (categorised), n (%) 40–60 187 (13.8) 344 (13) 73 (10.7) 64 (9.4)
61–80 980 (72.1) 1,914 (72.4) 549 (80.5) 553 (81.1)
>80 193 (14.2) 384 (14.5) 60 (8.8) 65 (9.5)
Sex, n (%) Male 911 (67) 1821 (68.9) 499 (73.2) 499 (73.2)
BMI, n (%) Underweight 10 (0.7) 18 (0.7) 0 (0) 0 (0)
Normal weight 215 (15.9) 394 (15) 67 (9.8) 67 (9.8)
Overweight 428 (31.7) 813 (30.9) 222 (32.6) 222 (32.6)
Obese 698 (51.7) 1409 (53.5) 393 (57.6) 393 (57.6)
Smoking status, n (%)‡ Non-smoker 141 (10.4) 265 (10.1) 31 (4.5) 31 (4.5)
Current smoker 414 (30.6) 882 (33.7) 194 (28.4) 194 (28.4)
Ex-smoker 800 (59.0) 1473 (56.2) 457 (67.0) 457 (67.0)
FEV1% predicted, n (%)‡ Missing 179 (13.2) 315 (11.9) 38 (5.6) 38 (5.6)
<30 (very severe) 48 (3.5) 37 (1.4) 22 (3.2) 11 (1.6)
30 –<50 (severe) 327 (24.0) 454 (17.2) 115 (16.9) 126 (18.5)
50 –<80 (moderate) 645 (47.4) 1,514 (57.3) 416 (61.0) 426 (62.5)
80 (mild) 161 (13.6) 322 (13.8) 91 (13.3) 81 (11.9)
mMRC score,[4] n (%) Missing 55 (4) 112 (4.2) 4 (0.6) 4 (0.6)
0–1 669 (49.2) 1429 (54.1) 383 (56.2) 383 (56.2)
2 636 (46.8) 1101 (41.7) 295 (43.3) 295 (43.3)
Acute OCS courses, n (%) 0 1005 (73.9) 2232 (84.5) 545 (79.9) 585 (85.8)
1 253 (18.6) 319 (12.1) 107 (15.7) 77 (11.3)
2 102 (7.5) 91 (3.4) 30 (4.4) 20 (2.9)
Moderate/severe exacerbations§, n (%) 0 590 (43.4) 1402 (53.1) 346 (50.7) 387 (56.7)
1 400 (29.4) 748 (28.3) 229 (33.6) 188 (27.6)
2 370 (27.2) 492 (18.6) 107 (15.7) 107 (15.7)
HbA1c (%, DCCT), n (%) 6.5% 458 (33.7) 809 (30.6) 214 (31.4) 197 (28.9)
6.5 –7.5% 531 (39.0) 1029 (38.9) 311 (45.6) 309 (45.3)
>7.5% 371 (27.3) 804 (30.4) 157 (23.0) 176 (25.8)
Antidiabetic medication, n (%) None 391 (28.7) 698 (26.4) 175 (25.7) 175 (25.7)
Non-insulin 771 (56.7) 1492 (56.5) 424 (62.2) 424 (62.2)
Insulin 198 (14.6) 452 (17.1) 83 (12.2) 83 (12.2)
GOLD group¶ Non-missing 1305 (96) 2530 (95.8) 678 (99.4) 678 (99.4)
A, n (%) 362 (27.7) 969 (38.3) 257 (37.9) 256 (37.8)
B, n (%) 292 (22.4) 684 (27.0) 186 (27.4) 187 (27.6)
C, n (%) 307 (23.5) 460 (18.2) 126 (18.6) 127 (18.7)
D, n (%) 344 (26.4) 417 (16.5) 109 (16.1) 108 (15.9)
*Includes prescriptions for SABA, SAMA, LABA, LAMA or their combinations. Patients may be included more than once with a different index date and
prescription. Number of unique patients: 2,007.
‡Data recorded at or closest to the index date. Percentages within categories calculated from non-missing values only.
§Defined as the number of acute oral corticosteroid courses and antibiotic prescriptions for a lower respiratory tract infection.
¶Closest to the index date, see supplementary methods (S1 File) for allocation into categories.
BMI = body mass index; COPD = chronic obstructive pulmonary disorder; DCCT = Diabetes Control and Complications Trial units; FEV1 = forced expiratory
volume in 1 second; GOLD = Global Initiative for Chronic Obstructive Lung Disease; HbA1c = glycated haemoglobin; ICS = inhaled corticosteroids;
LABA = long acting β2-agonist; LAMA = long acting muscarinic antagonist; mMRC = modified Medical Research Council; OCS = oral corticosteroids;
SABA = short acting β2-agonist; SAMA = short acting muscarinic antagonist; SD = standard deviation.
doi:10.1371/journal.pone.0162903.t002
Metabolic Effects of ICS in Patients with COPD and Comorbid Type 2 Diabetes
PLOS ONE | DOI:10.1371/journal.pone.0162903 September 22, 2016 6 / 17
Results
Matched patient population
There were initially 1,360 eligible patients in ICS cohort and 2,642 eligible patients in the
non-ICS cohort. After applying matching criteria, this was reduced to 682 unique patients in
each cohort (S2 Fig and S1 File). 442 patients in each cohort had mild-to-moderate COPD
(GOLD groups A and B), representing a similar proportion (65%) seen in previous data.[30]
In the unmatched population, 28% of mild-to-moderate patients were prescribed ICS during
the baseline period. The mean age of the full study sample was 70 years, and 73% were men;
95% of patients in each cohort were either current or ex-smokers, and 90% were either over-
weight or obese (Table 2). The spirometric severity of COPD was moderate in the majority
of patients, with a %predicted FEV1 of 50–79 for 61% and 62.5% of patients in the ICS and
non-ICS cohorts, respectively. The median (IQR) number of days between the baseline and
last HbA1c reading was 511 (386–596) and 526 (404–602) for ICS and non-ICS cohorts,
respectively.
Analysis of primary endpoint
Over the outcome period, an increase in HbA1c value was observed in both the ICS and non-
ICS cohorts (Table 3). However, patients prescribed ICS therapy experienced a significantly
greater increase in HbA1c from the baseline to the outcome period than those prescribed non-
ICS therapies (Fig 1); relative to the non-ICS cohort, the adjusted difference in change in
HbA1c (95% CI) was 0.16% (0.05–0.27%) in the full study sample (all COPD patients). This dif-
ference was also significant, and larger, in the mild-to-moderate COPD patients (adjusted dif-
ference [95% CI], 0.25% [0.10–0.40%]).
Analysis of secondary endpoints
The change in diabetes-related GP visits was significantly higher in the ICS cohort versus the
non-ICS cohort, in the full study sample (adjusted difference [95% CI], 0.31 [0.03–0.60]), but
not in the mild-to-moderate COPD patients (Fig 1). ICS-treated patients were significantly
Table 3. Study endpoints during the outcome year.
ICS cohort non-ICS
cohort
Change in HbA1c from baseline to outcome, median (IQR) 0.18 (-0.23,
0.60)
0.03 (-0.33,
0.50)
 0.5 (DCCT %) increase in HbA1c from baseline to outcome, n (%) 179 (29.9) 153 (25.5)
Addition of antidiabetic drug from baseline to outcome, n (%) 101 (16.9) 100 (16.7)
 0.5 (DCCT %) increase in HbA1c and/or addition of antidiabetic drug from
baseline to outcome, n (%)
240 (40.1) 223 (37.2)
HbA1c off QOF target (>7.5%), n (%) 209 (30.6) 194 (28.4)
Change in annual rate of diabetes-related GP visits, median (IQR) 0 (-1.01, 1.33) -0.01 (-1.34,
1)
Increase in diabetes-related hospitalisation rate, n (%) 41 (6.0) 31 (4.5)
Increase in prescription rate for glucose strips, n (%) 114 (16.7) 75 (11.0)
Progression to insulin, n (%) 28 (4.7) 12 (2.0)
DCCT = Diabetes Control and Complications Trial units; GP = general practice; HbA1c = glycated
haemoglobin; ICS = inhaled corticosteroids; IQR = interquartile range; OCS = oral corticosteroids;
QOF = Quality and Outcomes Framework.
doi:10.1371/journal.pone.0162903.t003
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more likely to increase the prescription rate for glucose strips from baseline to outcome period,
compared to non-ICS patients (Fig 2). This was found in all COPD patients and in the mild-
to-moderate subgroup. However, the adjusted odds of having an increase in HbA1c value and/
or an additional antidiabetic drug was only significant in the mild-to-moderate COPD patients
(odds ratio [95% CI], 1.45 [1.10–2.09], Fig 2).
A higher but non-significant proportion of patients in the ICS cohort who were prescribed
two or more types of non-insulin antidiabetic medication during the baseline year progressed
to insulin during the outcome period compared with those in the non-ICS cohort (unadjusted
proportions; S3 Fig). After confirming a valid proportional hazards assumption (S4 Fig), the
Fig 1. Comparison of changes in HbA1C and diabetes-related GP visits between ICS and non-ICS cohorts. Mild-to-
moderate COPD patients identified by GOLD groups A and B. *Adjusted for number of acute courses of OCS and diagnosis of
pneumonia during baseline, time between baseline and outcome HbA1c readings, and acute OCS use between index date and
outcome HbA1c readings. †Adjusted for diagnosis of GORD in baseline, baseline HbA1c, and duration of diabetes. ‡Adjusted for
number of acute OCS courses during baseline and time between baseline and outcome HbA1c readings. §Adjusted for baseline
HbA1c and duration of diabetes.CI = confidence interval; COPD = chronic obstructive pulmonary disease; HbA1c = glycated
haemoglobin; ICS = inhaled corticosteroids; GORD = gastro-oesophageal reflux disease; GOLD = Global Initiative for Chronic
Obstructive Lung Disease; GP = general practice; OCS = oral corticosteroids.
doi:10.1371/journal.pone.0162903.g001
Metabolic Effects of ICS in Patients with COPD and Comorbid Type 2 Diabetes
PLOS ONE | DOI:10.1371/journal.pone.0162903 September 22, 2016 8 / 17
time to progression to insulin showed no significant differences between patients prescribed
ICS vs non-ICS therapies (Fig 2). This could be due to the low number of patients progressing
to insulin (n = 28 and n = 12 for ICS and non-ICS cohorts, respectively. There was also no dif-
ference in progression to insulin in the mild-to-moderateCOPD subgroup. No significant dif-
ferences were observed in other measures of T2DM progression, including the number of
patients not reaching the QOF target for HbA1c (ie HbA1c>7.5%), or an increase in diabetes-
related hospitalisation rates (Table 3).
Fig 2. Comparison of other diabetes-related outcomes between ICS and non-ICS cohorts. Mild-to-moderate COPD patients
identified by GOLD groups A and B. *Adjusted for diagnosis of GORD in baseline, duration of diabetes, time between baseline and
outcome HbA1c readings, and acute OCS use between index date and outcome HbA1c readings. † Adjusted for number of allergy
prescriptions and number of primary care consultations in baseline. ‡ Adjusted for baseline antidiabetic medication. §Adjusted for
number of COPD consultations in baseline, time between baseline and outcome HbA1c readings, and acute OCS use between
index date and outcome HbA1c readings. ¶Adjusted for number of GP consultations in baseline. CI = confidence interval;
COPD = chronic obstructive pulmonary disease; HbA1c = glycated haemoglobin; ICS = inhaled corticosteroids; GORD = gastro-
oesophageal reflux disease; GOLD = Global Initiative for Chronic Obstructive Lung Disease; GP = general practice; OCS = oral
corticosteroids.
doi:10.1371/journal.pone.0162903.g002
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The effects of ICS dose
The adjusted odds of having a 0.5 (DCCT%) increase in HbA1c value and/or additional
antidiabetic medication were significantly greater for patients with a cumulative ICS dose
exposure of >250 mg (fluticasone equivalents) in the outcome period compared with those
with lower doses (125 mg). Patients with higher ICS dose exposure also experienced sig-
nificantly greater odds of being above QOF target for HbA1c (HbA1c>7.5%) in the outcome
period compared with those on lower doses (Fig 3). Results on time to insulin progression
are not presented in this case as the proportional hazards assumption was not valid. For
patients prescribed>250 mg ICS, the number needed to harm, NNH (95% CI), was esti-
mated to be 11 (6.2–39) compared with patients prescribed125 mg ICS. Thus, for every
11 patients prescribed>250 mg, 1 patient would have an increased risk of an increase in
HbA1c and/or receiving additional antidiabetic medication who would not have had this if
prescribed125 mg.
Fig 3. Adjusted odds ratios of the effect of cumulative ICS dose exposure and measured in fluticasone equivalents
from the first prescription at the index date to the last HbA1c value in the outcome period. *Adjusted for baseline HbA1c
and acute oral corticosteroid use between index date and outcome HbA1c. †Adjusted for duration of diabetes (combined first
diagnosis and first prescription), baseline HbA1c and acute oral corticosteroid use between index date and outcome HbA1c.
HbA1c = glycated haemoglobin; ICS = inhaled corticosteroids.
doi:10.1371/journal.pone.0162903.g003
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Discussion
Principal findings
In this historical matched cohort study, patients with COPD and comorbid T2DM who were
prescribed ICS experienced a significant negative impact on diabetes control in terms of
increase in HbA1c levels, diabetes-related general practice visits, and prescriptions of glucose
strips as compared with matched patients not prescribed ICS. Some effects were stronger in
mild-to-moderate COPD patients; an important finding, given that these patients should not
receive ICS according to treatment guidelines. Patients prescribed high doses of ICS were also
at greater risk of diabetes progression than those prescribed lower doses. These results were
demonstrated after adjustment for important clinical characteristics.
Clinical relevance
Despite finding significant differences in change in HbA1c levels between ICS and non-ICS
cohorts, these differences were small. Adjusted differences were 0.16% (ICS vs non-ICS) in the
full data set, and 0.25% in mild-moderate COPD patients. However, it should be noted that, in
the case of the mild-moderate patients, this difference was demonstrated in spite of the ICS
cohort beingmore likely to receive additional drugs to control their diabetes during the out-
come period. It should also be noted that the observedoutcome period varied between 12 and
18 months, due to the nature of the real-life data source. The average follow-up time was 1.4
years: if the study had measuredHbA1c change over one year, the observed change would be
approximately 0.11% (0.16/1.4). It is possible that such small changes accumulating over a lon-
ger time period could be clinically important, impacting on quality of life or the risk of long-
term diabetes complications, as discussed by McQueen et al[31]. This issue calls for further
research to investigate the long-term effects.
Strengths and limitations
This study drew on two large high-quality data sources, the CPRD and OPCRD, allowing us to
obtain a sizeable sample of a specific patient population with comorbid COPD and T2DM.
These data bases are well described and have previously been used in respiratory research.[19,
32] The primary data outcome, HbA1c value, is a reliable and clinically important marker of
glucose control in diabetes mellitus.[33, 34] We used an observational cohort design, which
reflects the real-life prescribing activity in our study population. A randomised controlled trial
(RCT), althoughmore rigorous in reducing bias in the comparison of treatment groups, would
not be practicable in this scenario. It would be unethical to randomise a severe COPD patient
to no ICS therapy, when ICS is the recommended treatment in national guidelines. For the
mild-moderate COPD patients, ICS therapy is not recommended. Yet because this recommen-
dation is frequently ignored, we were able to use observational data to make a clinically impor-
tant comparison between ICS and no ICS in this group of patients. Even so, as there is no
randomisation procedure in an observational study, systematic differencesmay arise between
two cohorts. In this study, we aimed to minimise these differences throughmatching of impor-
tant demographic and clinical characteristics, and through adjustment by other potential con-
founders. In particular, we ensured that variables that were likely to influence the level of
HbA1c, such as baseline HbA1c, antidiabetic medication and acute oral corticosteroid use,
were investigated as confounding factors. Despite these methods, there remains the possibility
of residual bias due to unmeasured confounders. It is unknown exactly why a GP may choose
to prescribe ICS to one patient while another GP prescribes no ICS to a similar patient. The
impact of such confounding, however, may be less in the mild-moderate group of our study,
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where treatment decisions are more subjective. It was in this group that we observed the stron-
gest negative effect of ICS. Our use of exact matching in the study design resulted in a large
reduction in sample size from 1,360 and 2,642 eligible patients to 685 matched patients in each
cohort.We accepted this reduction in order to maximise the balance of characteristics between
the two cohorts. However, the exclusion of patients may have made the final study sample less
representative of the patient population and therefore may affect the generalisability of our
results. The exclusion of patients due to a lack of HbA1c measurement may also contribute to a
decrease in generalisability. Further, to increase the number of patients that could be matched
we increased particular category sizes of matching variables. For example, we used an age cate-
gory of 70–75, so it should be noted that our analysis may have included comparisons between
70 year olds and 75 year olds. Such patients may differ in many ways, but we have matched by
important factors to maximise comparability.
Our primary endpoint captured the change in HbA1c over a period of 12–18 months. What
is not clear is whether the bulk of the change occurred at a particular point, or was gradual over
time. This is an interesting research question and should be considered for future study. In
addition, larger studies are recommended to detect a wider range of effect sizes.
Strengths and limitations in relation to other studies
In agreement with previous studies,[17, 18, 35, 36] we found that prescribing of ICS is not
restricted to patients with severe airflow limitation and/or those with two or more exacerba-
tions per year as recommended by GOLD guidelines. Of the eligible patients with mild to mod-
erate disease severity (GOLD groups A and B), 28% were prescribed ICS during the baseline
period. These patients were at increased risk for reduced glycaemic control during the outcome
period.However, previously published data regarding the effects of ICS on glucosemetabolism
are mixed.[37] Randomised controlled trials of ICS treatment in patients with COPD did not
identify increased rates of adverse diabetes-related events. This could be becausemost of these
trials relied on spontaneous adverse events rather than focusing on diabetes control. These
studies may therefore not have been powered to detect diabetes-related parameters, and they
may not have studied long enough outcome periods.[8, 26, 38–40] Conversely, real-life studies
have indicated significant detrimental effects of ICS on diabetes control.[6, 12] Our results
broadly agree with those of Suissa et al.,[6] who reported that ICS use was associated with an
increased risk of diabetes progression. We also found that patients with higher ICS dose expo-
sure are at significantly greater risk of diabetes progression, as assessed by both clinically rele-
vant increases in HbA1c and/or prescription of additional antidiabeticmedication, higher odds
of HbA1c values not meeting the QOF target, (HbA1c>7.5%), and increased glucose strip
prescriptions.
Meaning of the study
As evidenced by numerous studies, ICS use can have substantial adverse effects that need to be
weighed against the expected benefits for specific patients or patient groups.[9, 10, 41–44] In
the case of patients with COPD and T2DM, our results indicate that ICS therapy is associated
with a negative impact on diabetes control, and this effect increases with higher ICS doses.
Although ICS may be beneficial for reducing exacerbations in patients with severe COPD, [38,
45–47] the current guidelines for COPDmanagement do not indicate ICS treatment for
patients with less severe disease (GOLD groups A and B). Even so, a high proportion of these
patients are currently prescribed ICS, thereby exposing them to additional risks without bene-
fits, something that might be particularly relevant in a population where 90% of patients are
either overweight or obese. Our findings highlight the importance of multifactorial risk
Metabolic Effects of ICS in Patients with COPD and Comorbid Type 2 Diabetes
PLOS ONE | DOI:10.1371/journal.pone.0162903 September 22, 2016 12 / 17
assessment for patients with COPD, considering their risk factors for diabetes and other com-
mon comorbidities. Further research with longer outcome periods is required to determine the
effect of ICS use and cumulative dose on time to progression to insulin. Further research may
also consider a prospective cohort study in place of a retrospective study. Here, investigators
could arrange to capture evenmore measurements that may potentially confound the results,
and not have to rely only on the measurements that exist in historical data.
Conclusions
In conclusion, our results suggest that prescribing of ICS for patients with COPD and comor-
bid T2DM is associated with a negative impact on diabetes control, and patients with higher
ICS dose exposuremay be at a greater risk of diabetes progression than those with lower expo-
sure. Increased awareness of COPDmanagement guidelines is required to avoid putting this
patient group at unnecessary risk, and to assist patients and healthcare providers in making
informed decisions.
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